Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
KDP · NASDAQ · Soft Drinks & Non-alcoholic Beverages
Keurig Dr Pepper (KDP) · oqro.io/stocks/KDP · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Yes. Insiders of Keurig Dr Pepper (KDP) filed 1 open-market purchase in the last 90 days; the latest was filed on Aug 28, 2026.
Since 2008, Keurig Dr Pepper insiders reported 217 open-market purchases and 404 sales on Forms 4 and 5, with purchases in 15 different years, most recently 2026.
In the last 90 days, 2 insiders of Keurig Dr Pepper (KDP) reported 3 open-market sales worth $1.09M in total on SEC Form 4. The largest seller by value was Mary Beth Denooyer, with $778K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 1 trade in Keurig Dr Pepper (KDP) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent is from Sen. Alan Armstrong.
Keurig Dr Pepper's next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$35.01+0.22 (+0.63%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+27.7% (+$7.59) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $27.42 on Nov 18, 2025 to $35.01 on Nov 18, 2026 (+27.7%). Disclosed in this range: 5 insider trades, 0 pre-arranged insider sales, 1 Congress trade, and 40 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Soft Drinks & Non-alcoholic Beverages company based in Burlington, Massachusetts.
Last 12 months
+27.7%
Market value
$47.6B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 65.8M shares sold short (4.8% of shares outstanding), −21.7% vs the previous count, 4.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$7.34B
+70.6% vs the same quarter a year earlier
Free cash flow, last 12 months
$2.33B
This quarter $884M, a year earlier $527M
Net debt
$23.1B
Debt $24.4B, cash $1.29B, at Sep 30, 2026
Net income, last 12 months
$1.65B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Revenue, fiscal 2025
$16.6B
+8.2% vs the year before
Net income, fiscal 2025
$2.08B
As reported in the annual filing
Shares outstanding
1.36B
As of Nov 5, 2026
In fiscal 2025 the company spent $9M buying back its own shares and $1.25B on dividends. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Traded Sep 8 – Sep 9, 2026 · largest single transaction ~$391KNot reported under a pre-arranged trading plan
Sep 8, 2026~$391K · 12K sh @ $32.55
DetailsOfficial recordSep 9, 2026~$388K · 12K sh @ $32.30
DetailsOfficial recordInsider selling
Traded Sep 8 · filed the same day
A Keurig Dr Pepper officer told the SEC about a plan to sell $782K of Keurig Dr Pepper shares around Sep 8, 2026. The shares were not acquired as compensation.
Insider selling
Traded Sep 3 · filed 2 days laterNot reported under a pre-arranged trading plan
Since the trade +6.5% · S&P 500 −5.6% · to Nov 18
Keurig Dr Pepper's Senior VP & Controller sold $311K of Keurig Dr Pepper shares. The filing does not indicate a pre-arranged trading plan.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 14, 2025, KDP is up 28.2% and the index fund is up 9.0%: 19 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much KDP moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Insiders of Keurig Dr Pepper reported 217 open-market purchases and 404 sales since 2008; purchases in 15 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $250K1×1 trade | $1.09M3×3 trades |
| 2025 | $121M3×3 trades | $2.8B22×22 trades |
| 2024 | $17.6M5×5 trades | $8.04B13×13 trades |
| 2023 | $12.3M31×31 trades | $1.04B8×8 trades |
| 2022 | $8.65M17×17 trades | $59M17×17 trades |
| 2021 | $2.89M17×17 trades | $1.52B11×11 trades |
| 2020 | $405M24×24 trades | $8.9B11×11 trades |
| 2019 | $9.53M42×42 trades | $1.78B8×8 trades |
| 2018 | $8.22M31×31 trades | $7.71M4×4 trades |
| 2017 | — | $45.2M29×29 trades |
| 2016 | $64K1×1 trade | $40.4M30×30 trades |
| 2015 | — | $69.4M45×45 trades |
| 2014 | — | $65.6M45×45 trades |
| 2013 | $48K1×1 trade | $20.3M24×24 trades |
| 2012 | $83K2×2 trades | $41.3M52×52 trades |
| 2011 | $111K2×2 trades | $31.6M23×23 trades |
| 2010 | $2.02M33×33 trades | $2.11M20×20 trades |
| 2009 | — | $165K38×38 trades |
| 2008 | $527K7×7 trades | $12K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Keurig Dr Pepper over the 12 months to Nov 18, 2026: 1 FDA record and 2 executive contributions.
FMR LLC
Schedule 13G: passive · filed Aug 6, 2026 · 172M shares
Capital World Investors
Schedule 13G: passive · filed Nov 13, 2026 · 134M shares
BlackRock, Inc.
Schedule 13G: passive · filed Jul 29, 2026 · 116M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 99.7M shares
HARRIS ASSOCIATES L P
Schedule 13G: passive · filed Feb 17, 2026 · 86.3M shares
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
Notice · Federal Trade Commission
Granting of Requests for Early Termination of the Waiting Period Under the Premerger Notification Rules
Notice · Federal Trade Commission
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Last results
Nov 3, 2026
Within the 30 days after it, until Dec 3, 2026
Next results, expected
Feb 22, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
73%
125 of 171 insider purchases since 2018 came within 30 days after a results announcement
From Keurig Dr Pepper's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Keurig Dr Pepper's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
0 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Short sale volume: 45.6% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 53.1%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 583K shares (about $20.2M) were not delivered on time for settlement on Oct 19, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.